Who is at risk of low blood sugar on Wegovy, and what are the warning signs?

Patients with type 2 diabetes taking insulin or a sulfonylurea with Wegovy are at the highest risk for low blood sugar (hypoglycemia).

Understanding Low Blood Sugar (Hypoglycemia)

Hypoglycemia, or low blood sugar, is a condition where the level of glucose (sugar) in your blood drops to an abnormally low level. For most people, a blood glucose level below 70 milligrams per deciliter (mg/dL) is considered low and should be treated. Severe hypoglycemia is defined as a level below 54 mg/dL.

Glucose is the body's primary source of energy, and the brain is particularly dependent on it to function correctly. When blood glucose levels fall too low, your body may not have enough energy to carry out its normal functions, leading to a range of symptoms.

Wegovy (semaglutide) works by mimicking a hormone called GLP-1, which helps control blood sugar by stimulating insulin secretion only when blood glucose is high. This glucose-dependent mechanism means that Wegovy, when used alone, has a very low risk of causing hypoglycemia.

Primary Risk Factor: Concurrent Diabetes Medications

The most significant risk for developing low blood sugar while on Wegovy occurs in patients with type 2 diabetes who are also taking other medications that lower blood sugar. These primarily include insulin and drugs known as insulin secretagogues, such as sulfonylureas (e.g., glipizide, glyburide, glimepiride).

These medications lower blood glucose independently of the current glucose level. Combining them with Wegovy, which also has a glucose-lowering effect, can amplify the risk. The body's blood sugar can drop too much as a result of the combined therapeutic action.

Clinical trial data confirms this risk. In the STEP 2 trial involving patients with type 2 diabetes, severe hypoglycemia (<54 mg/dL) was reported in 6.2% of patients taking Wegovy compared to 2.5% on placebo. This risk increased to 30.1% for patients also using basal insulin.

Due to this increased risk, your physician may need to lower the dose of your concomitant insulin or sulfonylurea when you start or increase your dose of Wegovy. This is a critical safety measure to prevent potentially dangerous hypoglycemic events.

Hypoglycemia Risk in Patients Without Diabetes

For individuals taking Wegovy for chronic weight management who do not have type 2 diabetes, the risk of low blood sugar is very low. The drug's mechanism is designed to stimulate insulin release in response to high blood sugar, making it unlikely to cause hypoglycemia on its own.

Data from the STEP 1 clinical trial, which studied Wegovy in patients with overweight or obesity without diabetes, supports this. In this large study, clinically significant hypoglycemia (blood glucose <54 mg/dL) was a rare event.

The incidence of severe hypoglycemia was reported in only 0.4% of patients treated with Wegovy, which was very similar to the 0.2% rate observed in the placebo group. This indicates that Wegovy does not pose a significant hypoglycemia risk for this patient population when used as a monotherapy.

While the risk is minimal, it is not zero. It's still important to be aware of the symptoms and to discuss any concerns with your physician. You can find more information on GLP-1 medications on our main `/answers` page.

Warning Signs and Symptoms of Hypoglycemia

Recognizing the signs of low blood sugar is crucial for prompt treatment. Symptoms can be categorized as mild-to-moderate or severe.

Mild-to-moderate symptoms often appear first and include shakiness or trembling, sweating, chills, a fast heartbeat (palpitations), anxiety or nervousness, and intense hunger. You might also experience irritability, dizziness, or nausea.

Severe symptoms occur as blood sugar continues to drop, depriving the brain of glucose. These are more serious and can include confusion or delirium, blurred or double vision, difficulty speaking, clumsiness or poor coordination, drowsiness, and fatigue.

If left untreated, severe hypoglycemia can lead to loss of consciousness, seizures, or a coma. It is a medical emergency that requires immediate attention. It is helpful for family and friends to also be aware of these signs.

How to Manage and Prevent Low Blood Sugar

If you experience symptoms of hypoglycemia, you should check your blood sugar if possible. If it's below 70 mg/dL or you can't check it, follow the "Rule of 15." Consume 15 grams of fast-acting carbohydrates, such as 4 ounces of juice or regular soda, glucose tablets, or hard candies.

After consuming the carbohydrates, wait 15 minutes and then recheck your blood sugar. If it is still below 70 mg/dL, repeat the process. Once your blood sugar returns to a normal range, eat a small snack containing protein and carbohydrates to prevent another drop.

The best prevention strategy, especially for patients with type 2 diabetes, is proactive management under a physician's care. This includes regular blood glucose monitoring and communicating openly with your doctor about any hypoglycemic episodes. Your physician will determine if your other diabetes medications need to be adjusted.

Bottom Line

Wegovy is unlikely to cause low blood sugar when used alone for weight management in people without type 2 diabetes. The risk becomes significant for patients with type 2 diabetes who also use insulin or sulfonylureas.

Recognizing the warning signs—from shakiness and sweating to confusion—is essential for safety. Always follow the guidance of your physician, who can adjust your treatment plan to minimize risks and manage side effects effectively.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your treatment.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.